EUVIMEDEUVIMED entdecken
Crossref

Is Mixed Chimerism Post-allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoid Leukemia a Prognostic Factor for Relapse?

Saadiya Khan, Zainab AlSaif, Khawar Siddiqui, Hawazen AlSaedi, Ali Al-Ahmari, Abdullah Al-Jefri, Ibrahim Ghemlas, Awatif AlAnazi, Mouhab Ayas

Hematology/Oncology and Stem Cell Therapy · 2024

DOI: 10.56875/2589-0646.1112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2024. Verfasst von Saadiya Khan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Graft vs Host Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic stem cell transplantation (HSCT) has been considered curative for children with high-risk acute leukemia (ALL), offering better survival. Short tandem repeat has been used as a marker of chimerism status after HSCT. The appearance of recipient cells >1% post-allogeneic stem cell transplant is defined as mixed chimerism (MC). Chimeric studies post-HSCT are dynamic. This study aimed to investigate the significance of recipient cells in post- HSCT pediatric ALL patients as a predictor of relapse of their primary disease. The rate of MC was 51.4% (19 out of 37 recipients). It was 48.6% (n = 18) during Day+100 and 12.9% (4 out of 31 recipients) during post-Day+100 follow-up until two years. No significant association was noted between MC and all grade overall acute graft-versus-host disease. A mortality rate of 35.1% (n = 13) and a median follow-up of 56.9 months (95% CI: 39.7–74.2) were observed for all but four (16.7%) of the survivors in remission. Regarding causes of death, transplant-related mortality was recorded in only 2 of 13 expired patients (15.4%); both succumbed to sepsis. No significant association was found between MC and primary causes of death. The cumulative probability of five-year overall survival and event-free survival was not found to be statistically significantly different for MC (≤1.0% vs. > 1.0%). In conclusion, our data did not show MC testing alone as an effective prognostic marker for detecting relapse; molecular and flow cytometric analyses should be considered in children with ALL post-HSCT for monitoring relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaGraft vs Host DiseaseHumansChildPrognosisChimerismTransplantation, HomologousRecurrence

Autor:innen und Institutionen

  • Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Zitieren

APA

Khan, S., AlSaif, Z., Siddiqui, K., AlSaedi, H., Al-Ahmari, A., Al-Jefri, A., Ghemlas, I., AlAnazi, A., & Ayas, M. (2024). Is Mixed Chimerism Post-allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoid Leukemia a Prognostic Factor for Relapse?. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.56875/2589-0646.1112

Vancouver

Khan S, AlSaif Z, Siddiqui K, AlSaedi H, Al-Ahmari A, Al-Jefri A, et al. Is Mixed Chimerism Post-allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoid Leukemia a Prognostic Factor for Relapse?. Hematology/Oncology and Stem Cell Therapy. 2024. doi:10.56875/2589-0646.1112

BibTeX
@article{Khan2024,
  author = {Khan, Saadiya and AlSaif, Zainab and Siddiqui, Khawar and AlSaedi, Hawazen and Al-Ahmari, Ali and Al-Jefri, Abdullah and Ghemlas, Ibrahim and AlAnazi, Awatif and Ayas, Mouhab},
  title = {Is Mixed Chimerism Post-allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoid Leukemia a Prognostic Factor for Relapse?},
  journal = {Hematology/Oncology and Stem Cell Therapy},
  year = {2024},
  doi = {10.56875/2589-0646.1112}
}
Kostenlos starten →